Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
22
Bupropion 150 mg BID Bupropion Cmax ↓ 51% If the co-administration with
Bupropion AUC ↓ 56% bupropion is judged unavoidable,
this should be done under close
Tipranavir ↔ clinical monitoring for bupropion
efficacy, without exceeding the
The reduction of bupropion recommended dosage, despite the
plasma levels is likely due to observed induction.
induction of CYP2B6 and UGT
activity by RTV
Loperamide 16 mg QD Loperamide Cmax ↓ 61% A pharmacodynamic interaction
Loperamide AUC ↓ 51% study in healthy volunteers
demonstrated that administration
Mechanism unknown of loperamide and Aptivus, co-
administered with low dose
Tipranavir Cmax ↔ ritonavir, does not cause any
Tipranavir AUC ↔ clinically relevant change in the
Tipranavir Cmin ↓ 26% respiratory response to carbon
dioxide. The clinical relevance of
the reduced loperamide plasma
concentration is unknown.
Fluticasone propionate In a clinical study where ritonavir Concomitant administration of
Interaction study 100 mg capsules bid were co- Aptivus, co-administered with
performed only with administered with 50 µg low dose ritonavir, and these
ritonavir intranasal fluticasone propionate glucocorticoids is not
(4 times daily) for 7 days in recommended unless the
healthy subjects, the fluticasone potential benefit of treatment
propionate plasma levels outweighs the risk of systemic
increased significantly, whereas corticosteroid effects (see
the intrinsic cortisol levels section 4.4). A dose reduction of
decreased by approximately 86% the glucocorticoid should be
(90% confidence interval considered with close monitoring
82-89%). Greater effects may be of local and systemic effects or a
expected when fluticasone switch to a glucocorticoid, which
propionate is inhaled. Systemic is not a substrate for CYP3A4
corticosteroid effects including (e.g. beclomethasone). Moreover,
Cushing’s syndrome and adrenal in case of withdrawal of
suppression have been reported in glucocorticoids progressive dose
patients receiving ritonavir and reduction may have to be
inhaled or intranasally performed over a longer period.
administered fluticasone The effects of high fluticasone
propionate; this could also occur systemic exposure on ritonavir
with other corticosteroids plasma levels are as yet
metabolised via the P450 3A unknown.
pathway e.g. budesonide.
It is unknown whether the
combination of tipranavir with
ritonavir might cause a larger
increase in fluticasone exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Carboxylesterase 2 (CES2) inhibitors
The IC50 of the inhibition of loperamide on the metabolism of telotristat ethyl by CES2 was 5.2 µM
(see section 5.2). In phase 3 clinical studies, telotristat was routinely combined with loperamide with
no evidence of safety concerns.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Antidiarrhoeal loperamide
A clinical study has demonstrated that there were no clinically significant differences in the
exposure of subjects to neratinib with or without concurrent dosing with loperamide (see section
5.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
In healthy subjects, co-administration of abemaciclib and the P-glycoprotein (P-gp) substrate
loperamide resulted in an increase in loperamide plasma exposure of 9 % based on AUC0-∞ and 35 %
based on Cmax. This was not considered to be clinically relevant. However, based on the in vitro
inhibition of P-gp and breast cancer resistance protein (BCRP) observed with abemaciclib, in vivo
interactions of abemaciclib with narrow therapeutic index substrates of these transporters, such as
digoxin or dabigatran etexilate, may occur.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-08-25T14:25:00Z · SHA-256 c20dfe266c62d9e17c31fc34e43834efb72c38097be1ba0a86293f7d6f279ed0 · Passage 17e1ae32d2f49f83b1e0ca0cd20335613e3bc07289561fea38bec14d136b56ce · Zeichen 2458–2987 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.